Treatment with ORY-1001 alone resulted in only minor gene expression changes compared to the control (Fig. 3A), consistent with prior observations that MOLM-13, an acute monocytic leukemia (AML) cell line, is resistant to LSD1 inhibition [23]. The gene discussed is KDM1A; the disease is acute myeloid leukemia.